Dr. Steven Kirshblum, MD
Claim this profileKessler Institute for Rehabilitation
Studies Spinal Cord Injury
Studies Wounds and Injuries
10 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Steven Kirshblum, MD is currently running
Romosozumab + Denosumab
for Spinal Cord Injury
The objective of the proposed work is to determine whether administration for 12 months of romosozumab (evenity) followed by 12 months of denosumab (prolia) will maintain bone mass at the knee in subjects with chronic SCI.
Recruiting3 awards Phase 45 criteria
Shockwave Therapy
for Spinal Cord Injury
People with spinal cord injury (SCI) experience a host of secondary complications that can impact their quality of life and functional independence. One of the more prevalent complications is spasticity, which occurs in response to spinal cord damage and the resulting disruption of motor pathways. Common symptoms include spasms and stiffness, and can occur more than once per hour in many people with SCI. Spasticity can have a negative impact over many quality of life domains, including loss of functional independence, activity limitations, and even employment. Its impact on health domains is also pronounced, with many people who have spasticity reporting mood disorders, depression, pain, sleep disturbances, and contractures. Spasticity can interfere with post-injury rehabilitation and lead to hospitalization. There are many treatments for spasticity in this population. However, many do not have long-term efficacy, and, if they do, they are often pharmacological in nature and carry side effects that could limit function or affect health. The goal of this pilot, randomized-controlled study is to investigate the potential efficacy and safety of a non-invasive treatment with a low side effect profile, extracorporeal shockwave therapy (ESWT). ESWT has shown some benefits in people with post-stroke spasticity with no long term side effects. Thirty individuals with chronic, traumatic SCI will be recruited. Fifteen will be provided with ESWT while the other fifteen will be given a sham treatment. Clinical and self-report measures of spasticity and its impact on quality of life will be collected, as well as quantitative ultrasound measures of muscle architecture and stiffness. The ultimate goal of this pilot project is to collect the data necessary to apply for a larger randomized-controlled trial. Conducting a larger trial will allow for a more powerful estimation of safety and efficacy of ESWT as a treatment for spasticity in people with SCI.
Recruiting0 awards N/A6 criteria
More about Steven Kirshblum, MD
Clinical Trial Related2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Steven Kirshblum, MD has experience with
- Denosumab
- Romosozumab
- Romoszumab
- BQ 2.0
- Whole Body Vibration
- Mirabegron
Breakdown of trials Steven Kirshblum, MD has run
Spinal Cord Injury
Wounds and Injuries
Osteoporosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven Kirshblum, MD specialize in?
Steven Kirshblum, MD focuses on Spinal Cord Injury and Wounds and Injuries. In particular, much of their work with Spinal Cord Injury has involved treating patients, or patients who are undergoing treatment.
Is Steven Kirshblum, MD currently recruiting for clinical trials?
Yes, Steven Kirshblum, MD is currently recruiting for 4 clinical trials in West Orange New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Steven Kirshblum, MD has studied deeply?
Yes, Steven Kirshblum, MD has studied treatments such as Denosumab, Romosozumab, Romoszumab.
What is the best way to schedule an appointment with Steven Kirshblum, MD?
Apply for one of the trials that Steven Kirshblum, MD is conducting.
What is the office address of Steven Kirshblum, MD?
The office of Steven Kirshblum, MD is located at: Kessler Institute for Rehabilitation, West Orange, New Jersey 07052 United States. This is the address for their practice at the Kessler Institute for Rehabilitation.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.